Julie Cooke Sells 1,740 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Julie Cooke sold 1,740 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $152.89, for a total value of $266,028.60. Following the completion of the sale, the insider now owns 18,202 shares in the company, valued at approximately $2,782,903.78. This represents a 8.73 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Neurocrine Biosciences Stock Performance

NASDAQ NBIX opened at $150.51 on Friday. The firm’s 50 day moving average price is $138.41 and its two-hundred day moving average price is $131.64. Neurocrine Biosciences, Inc. has a twelve month low of $110.95 and a twelve month high of $157.98. The stock has a market cap of $15.24 billion, a price-to-earnings ratio of 40.35 and a beta of 0.33.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings results on Thursday, February 6th. The company reported $1.00 earnings per share for the quarter, missing the consensus estimate of $1.62 by ($0.62). Neurocrine Biosciences had a net margin of 17.21% and a return on equity of 15.68%. On average, research analysts forecast that Neurocrine Biosciences, Inc. will post 3.92 EPS for the current fiscal year.

Hedge Funds Weigh In On Neurocrine Biosciences

A number of large investors have recently made changes to their positions in NBIX. Golden State Wealth Management LLC acquired a new stake in shares of Neurocrine Biosciences during the fourth quarter worth approximately $25,000. Brooklyn Investment Group lifted its position in Neurocrine Biosciences by 99.1% in the 4th quarter. Brooklyn Investment Group now owns 231 shares of the company’s stock worth $32,000 after buying an additional 115 shares in the last quarter. Blue Trust Inc. boosted its stake in shares of Neurocrine Biosciences by 171.9% during the 3rd quarter. Blue Trust Inc. now owns 348 shares of the company’s stock valued at $40,000 after buying an additional 220 shares during the period. Lindbrook Capital LLC grew its holdings in shares of Neurocrine Biosciences by 53.5% during the 4th quarter. Lindbrook Capital LLC now owns 373 shares of the company’s stock valued at $51,000 after acquiring an additional 130 shares in the last quarter. Finally, R Squared Ltd acquired a new position in shares of Neurocrine Biosciences in the fourth quarter worth $61,000. Institutional investors and hedge funds own 92.59% of the company’s stock.

Analysts Set New Price Targets

NBIX has been the topic of a number of research analyst reports. Raymond James reissued an “outperform” rating and set a $155.00 price target on shares of Neurocrine Biosciences in a report on Thursday, October 10th. Wedbush reissued an “outperform” rating and set a $148.00 target price on shares of Neurocrine Biosciences in a research note on Monday, December 16th. UBS Group upped their price target on shares of Neurocrine Biosciences from $162.00 to $176.00 and gave the stock a “buy” rating in a research note on Thursday, January 30th. Piper Sandler reiterated an “overweight” rating and issued a $160.00 price objective on shares of Neurocrine Biosciences in a report on Monday, December 23rd. Finally, Barclays boosted their target price on Neurocrine Biosciences from $160.00 to $165.00 and gave the stock an “overweight” rating in a report on Monday, December 23rd. Five equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $166.85.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.